Amid string of splashy pandemic IPOs, ADC returns for its millions
Six months after withdrawing their bid for a massive IPO, ADC Therapeutics is back with a more conservative number: $100 million.
The Swiss biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
